Shuttle Pharmaceuticals is expected to report zero revenue and a projected EPS loss of -$0.43 for the second quarter, while its $3.53 stock price currently lacks a formal Wall Street consensus target.
The primary focus for investors is the company’s overdue Q2 2026 Form 10-Q filing and its urgent plan to regain Nasdaq compliance following a recent delisting notice.
Markets are specifically watching for the first detailed financial results following the merger with United Dogecoin and the strategic rebranding to United Compute Inc. This report is critical for assessing the liquidity risks and potential share dilution associated with the integration of crypto mining and AI operations.